ZUCLOPENTHIXOL ACETATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C24H27ClN2O2S
Molecular Weight	443.001
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(=O)OCCN1CCN(CC\C=C2\C3=C(SC4=C2C=C(Cl)C=C4)C=CC=C3)CC1

InChI

InChIKey=OXAUOBQMCDIVPQ-IOXNKQMXSA-N

InChI=1S/C24H27ClN2O2S/c1-18(28)29-16-15-27-13-11-26(12-14-27)10-4-6-20-21-5-2-3-7-23(21)30-24-9-8-19(25)17-22(20)24/h2-3,5-9,17H,4,10-16H2,1H3/b20-6-

HIDE SMILES / InChI

Description
Sources: http://www.lundbeck.com/upload/ca/en/files/pdf/pm/Clopixol.pdf
Curator's Comment: Description was created based on several sources, including https://www.lundbeck.com/upload/au/files/pdf/Clopixol_CMI.pdf | https://www.ncbi.nlm.nih.gov/pubmed/26624987

Zuclopenthixol is indicated the management of the manifestations of schizophrenia and other mental illnesses with disturbances in thinking, emotional reactions and behaviour. It is also used to treat the manic phase of manic depressive illness. Zuclopenthixol, a thioxanthene derivative, has high affinity for both dopamine D1 receptors and dopamine D2 receptors. Zuclopenthixol also has high affinity for α1-adrenergic and 5-HT2 receptors. Zuclopenthixol (CLOPIXOL®) is avavilable in the form of tablets and solution for intramuscular injections.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Dopamine D2 receptor 297 Target ID: CHEMBL217 Sources: http://www.lundbeck.com/upload/ca/en/files/pdf/pm/Clopixol.pdf	Antagonist 2778
Dopamine D1 receptor 101 Target ID: CHEMBL2056 Sources: http://www.lundbeck.com/upload/ca/en/files/pdf/pm/Clopixol.pdf	Antagonist 2778
Adrenergic receptor alpha-1 169 Target ID: CHEMBL2094251 Sources: http://www.lundbeck.com/upload/ca/en/files/pdf/pm/Clopixol.pdf	Antagonist 2778
Serotonin 2 (5-HT2) receptor 87 Target ID: CHEMBL2093870 Sources: http://www.lundbeck.com/upload/ca/en/files/pdf/pm/Clopixol.pdf	Antagonist 2778

Conditions

Condition	Modality	Targets	Highest Phase	Product
Schizophrenia 298 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26624987 http://www.lundbeck.com/upload/ca/en/files/pdf/pm/Clopixol.pdf https://www.lundbeck.com/upload/au/files/pdf/Clopixol_CMI.pdf	Primary		Approved 8429	CLOPIXOL Approved Use Zuclopenthixol is indicated the management of the manifestations of schizophrenia and other mental illnesses with disturbances in thinking, emotional reactions and behaviour. It is also used to treat the manic phase of manic depressive illness.
Bipolar disorder, manic phase 6 Sources: http://www.lundbeck.com/upload/ca/en/files/pdf/pm/Clopixol.pdf https://www.lundbeck.com/upload/au/files/pdf/Clopixol_CMI.pdf	Primary		Approved 8429	CLOPIXOL Approved Use Zuclopenthixol is indicated the management of the manifestations of schizophrenia and other mental illnesses with disturbances in thinking, emotional reactions and behaviour. It is also used to treat the manic phase of manic depressive illness.

PubMed

Title	Date	PubMed
The bucco-linguo-masticatory syndrome as a side-effect of neuroleptics therapy.	1967	4383787
The antibacterial effect of selected phenothiazines and thioxanthenes on slow-growing mycobacteria.	1986 Dec	3105243
Prolonged oculogyric crisis on addition of nifedipine to neuroleptic medication regime.	1987 Jan	3651662
Zuclopenthixol and perphenazine in patients with acute psychotic states. A double-blind multicentre study.	1987 Jul	3615572
Zuclopenthixol and haloperidol/levomepromazine in the treatment of elderly patients with symptoms of aggressiveness and agitation: a double-blind, multi-centre study.	1989	2568639
Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia.	1991 Dec	1822319
[acute dystonias in combined abuse of cocaine and neuroleptics].	1994 Nov 26	7990989
Long term results of unilateral posteroventral pallidotomy for antipsychotic drug induced tardive dyskinesia.	2005 Jul	15965227
[Trazodone for the treatment of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease: a retrospective study focused on the aggression and negativism in caregiving situations].	2006 Jun	16856516
Fatal exertional heat stroke in a patient receiving zuclopenthixol, quetiapine and benztropine.	2007 Fall	18025545
Remission of schizophrenia psychosis and strong reduction of obsessive-compulsive disorder after adding clozapine to aripiprazole.	2009 Nov 13	19766686
Severe laryngeal dystonia in a patient receiving zuclopenthixol "Acuphase" and fluoxetine.	2010 Apr	20175668
Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses.	2012 Apr 18	22513898
Simultaneous determination of 25 common pharmaceuticals in whole blood using ultra-performance liquid chromatography-tandem mass spectrometry.	2012 Sep	22718540

Patents

Sample Use Guides

In Vivo Use Guide

Clopixol tablets: The usual dose is 10 to 50 mg per day. Clopixol Acuphase injection: The usual dose is 50 to 150 mg (1 to 3 mL) every 2 to 3 days or as instructed by your doctor. Clopixol Depot injection: The usual dose is 200 to 400 mg (1 to 2 mL) every second to fourth week.

Route of Administration: Other

In Vitro Use Guide

Unknown

Name

Type

Language

ZUCLOPENTHIXOL ACETATE

Common Name

English

ZUCLOPENTHIXOL ACETATE [MART.]

Common Name

English

Zuclopenthixol acetate [WHO-DD]

Common Name

English

(Z)-4-(3-(2-CHLOROTHIOXANTHEN-9-YLIDENE)PROPYL)-1-PIPERAZINEETHANOL ACETATE

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29710